New: 50% response rate at RP2D in pancreatic cancer, presented at ESMO GI 2025
Contact · ImmunoMet Therapeutics

Get in touch

For investor enquiries, partnership discussions, or clinical questions, use the form below and the relevant team member will respond.

Send a Message

We'll get back to you promptly

Explore Further

More from ImmunoMet

Investors
Investment thesis & deck download →
Clinical
Phase 1b/2a trial data & design →
Pipeline
Full development programme →
Team
Leadership & clinical network →
Location
Dexter, Michigan
JLABS @ TMC · ImmunoMet Therapeutics, Inc.
Enquiries
Use the form — we reply directly
Investor, partnership, clinical & media